Product Description
AFNT-111 is a T-cell therapy being developed by AffiniT Therapeutics to target and treat cancers with a KRAS G12V mutation. (Sourced from: https://affinittx.com/wp-content/uploads/Affini-T_Non-Confidential_Deck_Jefferies_June-2022.pdf)
Mechanisms of Action: Cell Therapy
Novel Mechanism: No
Modality: Cell Therapy
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Affini-T Therapeutics
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| RG1123135 | P1 |
Suspended |
Oncology Solid Tumor Unspecified |
2026-02-09 |
50% |
2025-10-28 |